SBIR/STTR Research Award

CAD-CAM TECHNOLOGY FOR DIABETIC FOOTWEAR

Award identifier 0c5b3a118b27792e3077625bc1309be0368d06047a1631d0686671078793dfa3Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$199,143

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
DIAPEDIA, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
VCA7MUS7HJK3
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Adapted from the Investigator's Abstract): Gastrointestinal (GI) ulceration and hemorrhage is a major health problem in our country representing billions of dollars in health care costs and lost revenues from work place. Despite sophisticated therapeutic agents, the disturbing problem of high recurrence rate of bleeding, even after complete healing, remains. About one third of the patients treated with traditional ulcer therapy have recurrent hemorrhage. There is a need for developing new drugs that can arrest hemorrhage. In our pilot work we have shown that the organic extract of Chinese herbal preparation, Yunnan baiyao, has favorable influence on severe intestinal syndromes produced by indomethacin, and is also effective in promoting the healing and preventing GI ulcers in rat models. We have also shown that the extract contains at least two potent factors that induce aggregation of human platelets. We propose in this SBIR application to optimize methods for extraction as well as establish the molecular identity and mode of action of active principles that exhibit platelet aggregatory activities. We plan to carry out biological assays specific for anti-ulcerative and anti-hemorrhagic properties. The Phase I study will lay the foundation essential for the full development of the active factors into anti-hemorrhagic drug in Phase II studies. PROPOSED COMMERCIAL APPLICATION: The market for an effective and safe therapeutic agent to treat several types of hemorrhagic disorder notably bleeding from esophageal varices, gastric and duodenal ulcers will be enormous.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

14 SBIR/STTR records share this UEI (2001–2017). Reported award amounts total $9,092,425. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.